Profile data is unavailable for this security.
About the company
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
- Revenue in USD (TTM)21.05m
- Net income in USD-142.93m
- Incorporated2017
- Employees103.00
- LocationAlector Inc131 OYSTER POINT BLVD., SUITE 600SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 231-5660
- Fax+1 (302) 655-5049
- Websitehttps://alector.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Achieve Life Sciences Inc | 0.00 | -52.35m | 242.75m | 25.00 | -- | 7.16 | -- | -- | -1.38 | -1.38 | 0.00 | 0.6365 | 0.00 | -- | -- | 0.00 | -104.74 | -95.73 | -125.36 | -142.31 | -- | -- | -- | -- | -- | -- | 0.2271 | -- | -- | -- | -33.58 | -- | -- | -- |
| OmniAB Inc | 21.09m | -63.67m | 247.60m | 114.00 | -- | 0.8924 | -- | 11.74 | -0.5906 | -0.5906 | 0.1956 | 1.93 | 0.0658 | -- | 6.40 | 185,035.10 | -19.86 | -- | -20.75 | -- | 27.71 | -- | -301.83 | -101.09 | 4.96 | -- | 0.00 | -- | -22.75 | 7.58 | -22.55 | -- | 49.04 | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 247.84m | 15.00 | -- | 2.10 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
| Shattuck Labs Inc | 1.00m | -54.90m | 248.06m | 44.00 | -- | 2.66 | -- | 248.06 | -1.02 | -1.02 | 0.0178 | 1.48 | 0.0094 | -- | -- | 22,727.27 | -51.77 | -32.04 | -56.50 | -35.04 | -- | -- | -5,489.50 | -721.60 | -- | -- | 0.00 | -- | 245.26 | -10.36 | 13.62 | -- | -33.97 | -- |
| OpGen Inc | 9.00m | 6.70m | 248.66m | 1.00 | 37.20 | 24.29 | 36.09 | 27.63 | 0.6585 | 0.6585 | 0.8894 | 1.01 | 0.994 | -- | 4.42 | 9,000,000.00 | 75.58 | -74.71 | 81.77 | -111.02 | 100.00 | 30.79 | 76.04 | -602.64 | -- | -- | 0.00 | -- | 52.01 | 8.23 | 134.76 | -- | -- | -- |
| Sol Gel Technologies Ltd | 18.97m | -8.99m | 255.40m | 34.00 | -- | 9.81 | -- | 13.46 | -3.23 | -3.23 | 6.81 | 9.34 | 0.4891 | -- | 2.25 | 557,941.20 | -23.17 | -29.32 | -27.70 | -33.19 | -- | -- | -47.37 | -138.22 | -- | -- | 0.00 | -- | 642.47 | -12.81 | 61.16 | -- | -68.01 | -- |
| Silence Therapeutics plc | 25.81m | -65.01m | 256.95m | 115.00 | -- | 3.35 | -- | 9.96 | -0.462 | -0.462 | 0.1831 | 0.5227 | 0.1383 | -- | 124.98 | -- | -34.83 | -39.00 | -39.01 | -48.09 | 91.20 | 55.91 | -251.86 | -203.50 | -- | -- | 0.00 | -- | 36.71 | 168.26 | 16.45 | -- | 78.99 | -- |
| C4 Therapeutics Inc | 35.95m | -104.99m | 263.46m | 104.00 | -- | 1.02 | -- | 7.33 | -1.36 | -1.36 | 0.4337 | 2.65 | 0.1015 | -- | 13.06 | 345,644.20 | -29.63 | -27.16 | -33.31 | -30.47 | -- | -- | -292.08 | -328.00 | -- | -- | 0.00 | -- | 1.02 | 1.61 | 0.3058 | -- | -1.36 | -- |
| Palisade Bio Inc | 0.00 | -11.23m | 263.74m | 8.00 | -- | 5.03 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
| Alector Inc | 21.05m | -142.93m | 268.18m | 103.00 | -- | 8.75 | -- | 12.74 | -1.39 | -1.39 | 0.2043 | 0.2777 | 0.0553 | -- | -- | 204,320.40 | -37.54 | -18.23 | -50.42 | -22.68 | -- | -- | -679.16 | -100.47 | -- | -- | 0.2402 | -- | -79.07 | -0.0503 | -20.06 | -- | -61.79 | -- |
| Aardvark Therapeutics Inc | 0.00 | -48.77m | 271.95m | 33.00 | -- | 2.22 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 285.61m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 286.94m | 275.00 | -- | 0.0313 | -- | 1.27 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Alector Inc's reporting currency: US Dollar USD
30.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 6.30m | 5.77% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 5.54m | 5.08% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 3.44m | 3.15% |
| 683 Capital Management LLCas of 31 Dec 2025 | 3.35m | 3.07% |
| Balyasny Asset Management LPas of 31 Dec 2025 | 3.27m | 2.99% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 2.37m | 2.17% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 2.23m | 2.04% |
| Jacobs Levy Equity Management, Inc.as of 31 Dec 2025 | 2.17m | 1.99% |
| Ikarian Capital LLCas of 31 Dec 2025 | 2.08m | 1.91% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.08m | 1.90% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
